Danruo International Reproductive Hospital INCITA Fertility Center

I. Institutional Overview and Group Background

Danruo International Fertility Hospital(INCITA Fertility Center, whose English name was updated in sync with the brand upgrade to Dan Ruo Hospital) is the flagship directly operated institution under INCITA Fertility Group. Founded in 2018 in Phnom Penh, Cambodia, by Dr. Peng Wenlin, a leading expert in assisted reproductive technology, in collaboration with Macau Ivy Medical Center and US-based Yunsida Medical Group, it is the first third-generationTest tube babyA high-end reproductive genetics hospital with technology as its core feature, which has obtained a medical practice license from the Ministry of Health of Cambodia.

The hospital is positioned around the core principles of "high-standard laboratories and individualized treatment," with its clinical system benchmarked against internationally established standards for reproductive medicine centers. It serves patients from many regions worldwide, a significant proportion of whom present with complex or difficult cases, and most of whom have previously experienced unsuccessful treatments at other institutions.

The hospital is currently located on the 13th floor of the Flatiron by Meridian building in Phnom Penh City Center, Chamkar Mon District, Phnom Penh, Cambodia. This site also serves as the administrative and technical headquarters of Danuo Reproductive Medical Group. The institution was initially housed in Vattanac Capital before completing its relocation to the current campus.

II. Global Campus Layout

Danruo Reproductive Medical Group has established a cross-regional reproductive healthcare network. In addition to its flagship campus in Phnom Penh, it operates three regional centers, enabling coordinated medical resources and seamless cross-location care integration:

1. Phnom Penh Flagship Center, Cambodia: The Group's core technology and management headquarters, equipped with a full-process reproductive care system and high-standard clean laboratories, offering third-generation IVFFertility Preservationand complete diagnostic and treatment services.

2. Downtown Retail Center (DRC), Bangkok, Thailand: Rely onBangkokStrategically located for international medical tourism, we offer ovarian stimulation optimization and full-cycle clinical support. Our laboratory is built to equally high standards, with technical management overseen by senior embryologists.

3. China Hong Kong CenterProviding preliminary examinations, fertility assessments, and cross-border medical coordination services for individuals in the Greater Bay Area and mainland China, while holding relevant assisted reproduction practice licenses issued by local regulatory authorities.

4. Bogotá City Center, ColombiaServing the population of the Americas by providing reproductive healthcare solutions that comply with local laws and regulations, and supporting compliant cross-regional medical collaboration.

III. Qualification Certification and Laboratory Standards

HospitalEmbryology LaboratoryDesigned and constructed to international high standards, the facility is equipped with professional embryo culture and micromanipulation systems. It employs a temperature- and humidity-controlled clean environment management system to ensure stable embryo culture conditions, providing robust hardware support for the development of high-quality embryos and blastocysts.

established within the hospitalPGTTesting laboratory, obtainDual accreditation by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA)The test results are internationally credible, and the facility offers whole-chromosome screening and single-gene genetic disease testing.

IV. Core Medical Team

The hospital adopts a full-time expert residency model, with both clinicians and embryologists working on-site full-time to ensure the continuity and consistency of treatment protocols. The core team brings extensive experience from top-tier domestic hospitals and overseas reproductive centers.

• Peng Wenlin, Dean / Chief EmbryologistWith over two decades of experience in clinical and laboratory management within assisted reproductive technology (ART), he previously worked at the Reproductive Medicine Center of the First Affiliated Hospital of Sun Yat-sen University, served as the Laboratory Director at the Reproductive Medicine Center of Hong Kong Sanatorium & Hospital (where he completed Hong Kong’s first successful pregnancy case using in vitro maturation of immature oocytes), and later held the position of Laboratory Director at New Hope Fertility Center in the United States. In 2014, he founded Macau Ivy Medical Center, and in 2018, he spearheaded the establishment of Danuo International Reproductive Hospital. He has extensive expertise in embryo culture,Embryo biopsyIn the PGT field, we have long-term technical expertise in oocyte cryopreservation and personalized culture protocols for cases with repeated failures.

• Team ConfigurationPhnom Penh General Hospital is staffed by multiple reproductive endocrinologists and senior embryologists with an average of over 20 years of experience, and also features dedicated genetic counseling services. The team includes laboratory technicians holding the American High Complexity Clinical Laboratory Director (HCLD) certification, as well as reproductive endocrinology specialists with more than thirty years of clinical experience.

• Technical Lead for Bangkok CenterDr. Songguo Xue, a senior embryologist formerly affiliated with the Ninth People’s Hospital of Shanghai Jiao Tong University School of Medicine, serves as Scientific Director. He holds multiple domestic and international technology patents and specializes in challenging embryo culture cases and repeated fertilization failures.

  

V. Core Technologies and Clinical Services

1. Core Technologies

• Preimplantation Genetic Testing for Aneuploidy, Monogenic/Single Gene Defects, and Structural Rearrangements (PGT-A/M/SR): Includes preimplantation genetic testing for aneuploidy (PGT-A), monogenic disorders (PGT-M), and structural rearrangements (PGT-SR). It enables the selection of chromosomally normal embryos for transfer, thereby blocking the transmission of monogenic diseases and reducing the risks of implantation failure and miscarriage caused by chromosomal abnormalities.

• Vitrification: Applied to the cryopreservation of oocytes, embryos, and sperm, with an officially reported oocyte thaw survival rate of 95%; supports male fertility preservation solutions such as single-sperm freezing, suitable for special conditions including azoospermia and cryptozoospermia.

• In Vitro Maturation (IVM) of Immature OocytesBy using a specialized culture medium to simulate the in vivo maturation environment of oocytes, we provide diagnostic and treatment pathways for individuals with oocyte maturation disorders. This is one of our institution’s signature technical specialties.

2. Routine Medical Services

• Basic Assisted Reproductive Technologies: Intracytoplasmic Sperm Injection (ICSI), Blastocyst Culture, Embryo Cryopreservation and Thawing, Reproductive Endocrine Regulation

• Fertility Preservation: Egg Freezing for Women, Sperm Freezing for Men

• Artificial insemination: Intrauterine insemination (IUI), intracervical insemination (ICI)

• Management of Difficult Cases: Recurrent Implantation Failure, Advanced Maternal Age with Poor Ovarian Response, Severe Oligoasthenozoospermia or Azoospermia, and Recurrent Fertilization Failure

• Genetic Disease Prevention: Preimplantation Genetic Testing and Genetic Counseling for Families with Monogenic Disorders

VI. Clinical Data Description

The following data are derived from internal clinical statistics officially published by the institution and are for reference at the population level only:

• For first-time IVF patients who underwent PGT testing, the officially announced clinical pregnancy rate was 83.2%.

• Among patients with repeated failures at external clinics who were referred, the officially announced clinical pregnancy rate was 66.8%.

• The overall clinical pregnancy rate of the institution ranges from 65% to 78%, with relatively stable clinical outcomes maintained among patients with complex cases.

Important Note: Clinical outcomes of assisted reproductive technology are influenced by multiple individual factors, including patient age, ovarian reserve, and the complexity of underlying causes. The data above represent population-level statistics, do not reflect individual treatment results, and do not constitute any guarantee of efficacy.

7. Appointment Process and Supporting Services

Standard Clinical Workflow

1. Preliminary Consultation and AssessmentSubmit your previous medical records and examination reports via the official Chinese customer service to obtain a preliminary diagnostic assessment and treatment plan recommendations.

2. Remote Video ConsultationConduct a video consultation with the attending physician or hospital director to confirm the treatment plan and the applicability of the technology.

3. Travel Preparation: Customer service assists with entry-related procedures, and accommodation at self-operated apartments near the campus can be reserved.

4. Inpatient cycle treatment: The full process of ovulation induction, egg retrieval, ICSI fertilization, embryo culture, PGT testing, and blastocyst transfer is completed at the Phnom Penh campus, with Chinese-speaking medical staff available throughout.

5. Postoperative follow-up: After returning to your home country, you can receive remote prenatal monitoring and follow-up guidance, or opt for in-person check-ups at our group’s centers in Hong Kong or Bangkok.

   

Amenities and Services

• Self-operated companion apartments: Located around the campus, offering 24-hour security and on-site nursing services

• End-to-end Chinese medical guidance and translation services to eliminate language barriers in cross-border healthcare

• Supports multiple payment methods, including credit cards and mobile payments.

• The facility offers free Wi-Fi, accessibility features, and a comfortable clinical environment.

  

8. Compliance Tips for Cross-Border Medical Care

1. Legal Compliance RequirementsCross-border assisted reproductive care must comply with the laws and regulations of both China and the country where treatment is sought. Chinese law explicitly prohibits surrogacy, fetal sex determination for non-medical reasons, and sex-selective induced abortion. It is advisable to thoroughly understand the relevant legal provisions in both countries before seeking medical care and assess associated legal risks.

2. Medical Risk AlertCross-border healthcare involves potential risks such as regional disparities and difficulties in coordinating follow-up care. It is recommended to choose institutions with proper qualifications, maintain complete medical records, and safeguard your rights and interests.

3. This article is an objective introduction to institutional information only and does not constitute medical advice or recommendations for seeking care. For specific treatment plans, please consult professional medical personnel.

IX. Precautions for Medical Visits

1. Brand Name Explanation"INCITA Fertility Center" and "Dan Ruo Hospital" refer to the same medical institution. The change reflects an upgrade in the English brand name, with no modifications to the medical team, campus address, or technical standards.

2. Channel Risk WarningThe institution previously issued a statement reminding the public to be vigilant against third-party organizations falsely using experts' names for misleading advertising and charging fees. It recommended that inquiries and appointments be made through official channels, and advised against handling related services via unauthorized intermediaries.

3. Principle of individualized treatmentAssisted reproductive treatment plans are highly individualized. It is recommended that you bring your complete medical history and test reports to obtain a personalized assessment and cost explanation through official channels.